SEC Filing Summary: Alphabet Inc. Form 13F
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. for the reporting period ending September 30, 2021. The document discloses the equity securities held by Alphabet Inc. at the end of the quarter. It does not contain Alphabet's own financial performance data (revenue, profit, cash flow) but rather details its investment portfolio in other public companies.
Key Financial Metrics and Portfolio Composition
The filing lists Alphabet's holdings in various issuers, primarily within the biotechnology, healthcare, and technology sectors. Key metrics provided include the number of shares held and the aggregate market value of each position (in thousands of dollars).
- Top Holdings by Value:
- Oscar Health Inc.: Multiple positions totaling approximately $24.0 million (21.3M + 1.96M + 0.48M + 0.25M).
- UiPath Inc.: Multiple positions totaling approximately $17.6 million (13.66M + 3.92M).
- Verve Therapeutics Inc.: Multiple positions totaling approximately $11.0 million (10.79M + 0.18M).
- Benson Hill Inc.: Approximately $14.8 million.
- Lyell Immunopharma Inc.: Approximately $5.9 million.
- Investment Discretion: The filing indicates "DFND" (Discretionary) for all listed positions, with varying levels of sole, shared, or none voting authority.
- Liquidity and Debt: The filing text does not provide data on Alphabet's corporate liquidity, debt levels, or cash flow.
Material Changes and Comparisons
The provided text contains only the snapshot of holdings as of September 30, 2021. It does not include the prior quarter's data (June 30, 2021) or a schedule of purchases and sales. Therefore, material changes versus the prior comparable period cannot be determined from this specific document.
Guidance, Outlook, and Risks
Management Commentary: None provided. Form 13F is a regulatory disclosure of holdings and does not contain management commentary, forward-looking guidance, or strategic outlook.
Risks and Contingencies: The filing includes a standard disclaimer stating that the SEC has not reviewed the information for accuracy or completeness. No specific risk factors or contingencies regarding the portfolio are detailed in the text.
Unusual Items: The portfolio shows significant concentration in pre-IPO or recently public biotechnology and health-tech firms (e.g., Verve, Lyell, Oscar Health), which may indicate a strategic venture capital-style investment approach by Alphabet's investment arm.
Investor Verification Checklist
- Verify the total aggregate value of Alphabet's disclosed equity portfolio by summing the "Value" column (noted as x$1000 in the header).
- Compare these holdings against Alphabet's 10-Q or 10-K filings to understand how these investments are classified (e.g., available-for-sale securities, equity method investments) and their impact on Alphabet's consolidated balance sheet.
- Check subsequent 13F filings to determine if these positions were held, increased, or liquidated in the following quarter.
- Confirm the voting authority status (Sole, Shared, None) for the largest positions to assess Alphabet's potential influence on the governance of these investee companies.